



# CSL Research Acceleration Initiative

## Seeking Expressions of Interest from Research Organizations

### WHY COLLABORATE WITH CSL?



**Global** capabilities on your doorstep.



**Work** with one of the world's leading biotech companies.



**Funding** for successful proposals.



**Access** to commercial R&D, clinical, intellectual property, marketing and manufacturing expertise.



**Accelerate** translation of your research to deliver new therapies to patients.

CSL is a leading global biotechnology company committed to developing and delivering innovative biotherapies to improve the lives of people with serious and life-threatening medical conditions.

CSL's **Research Acceleration Initiative** aims to accelerate discovery of innovative biotherapies through partnerships between CSL and global research organizations. These partnerships provide funding and access to industry experts for scientists working on novel biotherapeutic strategies in CSL's therapeutic areas.

**Expressions of interest** are sought from Business Development / Commercialization representatives that wish to register their research organization to participate in the 2026 CSL Research Acceleration Initiative.

The 2026 Research Acceleration Initiative will focus on innovative research projects that address unmet medical needs and are aligned with CSL's **Therapeutic Areas**.



# CSL Research Acceleration Initiative

## Additional Information

---

### REGISTER YOUR RESEARCH ORGANIZATION

BD and Commercialization representatives from research organizations (universities, medical research institutes, hospitals) and companies (start-ups, biotechs) are invited to register their organization's interest to participate in the 2026 Research Acceleration Initiative. Please email **RAI@csl.com.au** **no later than 12<sup>th</sup> December 2025** expressing your interest to participate.

### NOMINATE YOUR PRIMARY CONTACT

CSL requests that each research organization and company nominate **one** BD or Commercialization representative to act as the primary point of contact with CSL.

### CALLS FOR SCIENTIFIC PROPOSALS

CSL will work with nominated BD or Commercialization representatives from participating research organizations and companies to seek scientific proposals that align with the focus areas of the 2026 Research Acceleration Initiative. Focus areas will be communicated with registered organizations via webinars and flyers ahead of online applications opening. Scientists who wish to apply will be invited to submit a 300-word online abstract outlining their proposal. Online submission of abstracts will open in January 2026. Online information sessions for scientists will be run in February 2026.



### LIMITATIONS ON ABSTRACT SUBMISSIONS

There is **no limit** on the number of abstracts that registered research organizations or individual researchers can submit.

### FUNDING

Successful applicants will receive up to \$200,000 USD per year over two years (up to \$400,000 USD in total) to accelerate translation of their research.

Funding is subject to successful execution of a research funding and option agreement between CSL and the partner organization.